Evidence map›Paper›PMID 22546039›Full record

ArticleBreast cancer research : BCR2012

Adjuvant treatment of HER2-positive breast cancer: winning efforts continue to improve HER2-positive patient outcome long-term.

Rachel C Jankowitz, Adam M Brufsky

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Breast cancer research : BCR, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04172259 (A Multi-center Randomized Phase II Study of Doxorubicin Liposome Versus Epirubicin Plus Cyclophosphamide Combined With Trastuzumab and Pertuzumab), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04172259 phase2active not recruitingnot on this mapstarted 2019, after this paper: background citation

A Multi-center Randomized Phase II Study of Doxorubicin Liposome Versus Epirubicin Plus Cyclophosphamide Combined With Trastuzumab and Pertuzumab(HP), Followed by Taxon Plus HP as Neoadjuvant Therapy for HER2-positive Early Breast Cancer

TypeinterventionalSponsorSun Yat-sen UniversityRan2019 to 2026Enrolled156ConditionsBreast Cancer, Neoadjuvant ChemotherapyArmsDoxorubicin liposome, Cyclophosphamide, Trastuzumab, Docetaxel, Epirubicin
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Rachel C JankowitzUniversity of Pittsburgh Cancer Institute, Magee-Women's Hospital, 300 Halket Street, Suite 4628, Pittsburgh, PA 15213, USA.
Adam M Brufsky

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Randomized adjuvant trials continue to show significant reductions in distant recurrence and death for early-stage women treated with adjuvant trastuzumab. BCIRG-006 showed superior disease-free and overall survival of two trastuzumab-containing regimens in comparison to a non-trastuzumab-containing regimen. The rates of disease-free and overall survival were not statistically different for the two trastuzumab-containing arms. Ongoing study is needed to identify markers of resistance to trastuzumab and incorporate newer agents in the adjuvant setting in order to further decrease rates of distant recurrence and death from HER2-positive breast cancer.

Indexed as

Antibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsCarboplatinChemotherapy, AdjuvantDisease-Free SurvivalDocetaxelErb-b2 Receptor Tyrosine KinasesFemaleHeart FailureHumansRandomized Controlled Trials as TopicTaxoidsTrastuzumabAntibodies, Monoclonal, HumanizedCarboplatinDocetaxelERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesTaxoidsTrastuzumab

Identifiers

PMID22546039
PMCPMC3446365

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.